Correction: Circulating microRNA signature as liquid-biopsy to monitor lung cancer in low-dose computed tomography screening

This article has been corrected: In the Introduction section, the second sentence of the second paragraph was worded incorrectly. The proper sentence is as follows:

A significant reduction in lung cancer mortality was reported among the subjects enrolled in the LDCT arm of the National Lung Screening Trial (NLST) when compared to the chest X-ray arm, along with a false discovery rate of 96.4% and an overdiagnosis global rate of 18.5%, reaching 78.9% for indolent cancers in the LDCT arm.

Original article: Oncotarget. 2015; 6:32868–32877. 32868-32877. https://doi.org/10.18632/oncotarget.5210